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Abstract
Primary splenic lymphomas (PSL) are rare malignancies which involve spleen with or without splenic hilar lymph nodes. Confir-
mation of diagnosis depends upon tissue sampling but noninvasive methods are useful in early diagnosis, treatment response 
monitoring and recurrence detection. Here we describe a case of PSL detected by 18F-FDG-PET/CT which was histopathologi-
cally proven to be diffuse large B-cell lymphoma (DLBCL) treated with CHOP regimen. 18F-FDG-PET/CT was found to be very 
useful in all stages (staging, recurrence detection and treatment response monitoring) of PSL with eight years of follow up.
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Background
Malignant cells are usually hypermetabolic so they use ex-
cess glucose which is the principle used in 18F-fluorodeoxyglucose 
(18F-FDG) positron emission tomography/computed tomography 
(PET/CT). PET/CT can identify functional hypermetabolic lesion even 
in the absence of any anatomically visible disease. 18F-FDG-PET/CT 
is proven to be useful in staging of both Hodgkin’s disease and 
NHL [1]. It has very high sensitivity, specificity, PPV and NPV in dif-
ferentiating benign from malignant splenic lesion [2]. But there are 
very few (to our knowledge only 2) case reports about 18F-FDG-PET 
in detection of primary splenic lymphoma (PSL) [3, 4]. Here we 
present a case of PSL patient who underwent serial 18F-FDG-PET/CT 
scans in our department in last 8 years and 18F-FDG-PET/CT proved 
to be of great value in staging, treatment response evaluation and 
recurrence detection. 
Case report 
A 44-year-old male presented with fever for 1 month with asso-
ciated heaviness on left upper abdomen. Infectious disease screening 
for malaria, enteric fever was negative. There was no derangement 
in liver or kidney function test. Hematological investigations revealed 
mild anemia with hemoglobin 8.8 gm/dl which was normochromic 
normocytic but normal leukocyte and platelet count. His LDH 
was 660 IU/L. He underwent abdominal ultasonography which 
revealed splenomegaly with normal echotexture. An abdominal 
CT scan showed diffusely hyperdense spleen with no other lym-
phadenopathy. He also underwent bone marrow biopsy which 
showed no lymphomatous involvement. He was then referred for 
18F-FDG-PET/CT to look for other organ involvement. 18F-FDG-PET/CT 
study revealed enlarged spleen with diffuse increased 18F-FDG 
uptake (Figure 1). No other focus of abnormal 18F-FDG uptake 
was noted which was consistent with PSL Ahmann stage 1 [5]. 
As the patient did not give consent for splenectomy, on suspicion 
of splenic lymphoma splenic biopsy was performed  [6]. Splenic 
biopsy confirmed it as diffuse large B-cell lymphoma (DLBCL). He 
was then put on 6 cycles of chemotherapy consisting of Cyclophos-
phamide, Adriamycin, Vincristine and Prednisone. Post therapy 
scan shows resolution of lesion (Figure 2A–D). The patient was on 
3 monthly follow-up and 18F-FDG-PET/CT was performed yearly. Two 
years after the detection of PSL his PET/CT showed recurrence of the 
disease; this was confined to spleen and retroperitoneal lymph node 
(Figure 2E–H) only though the patient was asymptomatic. This time 
the patient was treated with RICE regimen consisting of Rituximab, 
Ifosfamide, Carboplatin and Etoposide. Splenectomy was not 
performed due to patient’s refusal. After 3 cycles of chemotherapy 
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PET/CT showed complete resolution of the disease and he is on 
follow up. Presently he is in his eighth year of follow up. He is asymp-
tomatic and his last two PET/CT scans were normal (Figure 2I–P). 
Discussion
Lymphomatous involvement of spleen is a common occur-
rence. Both conventional imaging like computerized tomography, 
ultrasonography and functional imaging like 18F-FDG-PET or PET/CT 
can be used to assess the splenic involvement. 18F-FDG-PET/CT 
is already widely acceptable tool for accurate staging for Hodg-
kin’s (HD) and non-Hodgkin’s lymphoma (NHL) [7]. Few stud-
ies have also showed its usefulness in detecting splenic lesions. 
18F-FDG-PET/CT had 100% sensitivity and 95% specificity in detect-
ing splenic involvement in malignant lymphoma in a study by De 
Jong et al. [2]. Metser et al. proposed an SUV threshold of 2.3 to 
have a 100% sensitivity, specificity, PPV and NPV in differentiating 
benign from malignant solid splenic masses. Using splenic uptake 
greater than hepatic uptake as the criterion for a positive study, the 
sensitivity, specificity, and accuracy of 18F-FDG-PET/CT were 92%, 
100%, and 97% respectively in their study [8]. In another study 
Rini et al. found PET/CT to have 100% sensitivity in comparison to 
only 57% for conventional CT scan in detecting splenic lesions in 
lymphoma [9]. But lymphoma restricted to spleen known as PSL 
is extremely rare. To our knowledge, there are only two case re-
ports where 18F-FDG-PET/CT aided in the diagnosis of PSL [3, 4]. 
Our experience with this case documents that 18F-FDG-PET/CT 
is a very useful tool in all stages (diagnosis, staging, recurrence 
detection and treatment response monitoring) of PSL with eight 
years of follow up.
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Figure 1. Baseline 18F-FDG-PET/CT study. Trans-axial (A–C), coronal 
(D–F) and sagittal (G–I) views of PET (A, D, G), CT (B, E, H) and 
PET/CT (C, F, I) images revealing 18F-FDG avid enlarged spleen with 
diffuse uptake
Figure 2. Serial follow-up 18F-FDG-PET/CT studies. Maximum intensity 
projection PET (A) and transaxial PET (B), CT (C) and PET/CT 
(C) images of post chemotherapy 18F-FDG-PET/CT scan showing 
resolution of lesion (A–D). Subsequent follow-up study (E–H) showed 
recurrence of the disease which was confined to enlarged spleen 
(arrow) and retroperitoneal lymph node (dotted arrow). After change 
in chemotherapy regimen, subsequent follow-up PET/CT studies were 
normal (I–P)
